Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

EMA's Advisory Committee Recommends Approval Of Bristol-Myers' Breyanzi In Lymphoma

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Bristol-Myers Squibb Co (NYSE:BMY) Breyanzi (lisocabtagene maraleucel; liso-cel) for lymphoma settings.

  • The recommendation covers Breyanzi for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B) after two or more lines of systemic therapy.
  • The CHMP adopted a positive opinion based on TRANSCEND NHL 001, and additional data from the TRANSCEND WORLD study. 
  • The EC is expected to deliver its final decision within 67 days of receiving the CHMP opinion.
  • Price Action: BMY shares are up 0.77% at $64.35 during the market session on the last check Friday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.